Biological markers for axonal degeneration in CSF and blood of patients with the first event indicative for multiple sclerosis

被引:75
作者
Hein , Katharina [1 ]
Koehler, Anushka [1 ]
Diem, Ricarda [2 ]
Saettler, Muriel B. [1 ]
Demmer, Iris [1 ]
Lange, Peter [1 ]
Baehr, Mathias [1 ]
Otto, Markus [3 ]
机构
[1] Neurol Univ Klin, D-37075 Gottingen, Germany
[2] Neurol Univ Klin, Hamburg, Germany
[3] Neurol Univ Klin, Ulm, Germany
关键词
multiple sclerosis; axonal damage; biomarkers; cerebrospinal fluid; neuron specific enolase;
D O I
10.1016/j.neulet.2008.02.064
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Axonal degeneration is now recognized as an important pathological feature of multiple sclerosis (MS). Acute axonal damage happens early in the disease course, and therefore early changes might occur in markers in body fluids, such as cerebrospinal fluid (CSF) and blood. In our study we investigated the relevance of serum and CSF markers for axonal damage in patients with clinically isolated syndrome indicative for MS. We measured the concentration of tau, phospho-tau, S100B, Amyloid beta and neuron specific enolase (NSE) in CSF and serum. Interestingly, the NSE concentration in CSF and serum was decreased in clinically isolated syndrome (CIS)-patients in comparison to the control group indicating reduced neuronal metabolic activity in the early stage of the disease. Concerning other biomarkers, we did not observe any changes in the concentrations between groups. Moreover, we did not detect any correlation between Expanded Disability Status Scale (EDSS) and the concentration of investigated proteins. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:72 / 76
页数:5
相关论文
共 39 条
[1]  
BINDER LI, 1985, J CELL BIOL, V101, P1371, DOI 10.1083/jcb.101.4.1371
[2]   Tau protein level in cerebrospinal fluid is increased in patients with early multiple sclerosis [J].
Brettschneider, J ;
Maier, M ;
Arda, S ;
Claus, A ;
Süssmuth, SD ;
Kassubek, J ;
Tumani, H .
MULTIPLE SCLEROSIS JOURNAL, 2005, 11 (03) :261-265
[3]   The 14-3-3 protein in multiple sclerosis: a marker of disease severity [J].
Colucci, M ;
Roccatagliata, L ;
Capello, E ;
Narciso, E ;
Latronico, N ;
Tabaton, M ;
Mancardi, Gl .
MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (05) :477-481
[4]   SERUM NEURON-SPECIFIC ENOLASE CONCENTRATIONS IN PATIENTS WITH NEUROLOGICAL DISORDERS [J].
CUNNINGHAM, RT ;
MORROW, JI ;
JOHNSTON, CF ;
BUCHANAN, KD .
CLINICA CHIMICA ACTA, 1994, 230 (02) :117-124
[5]   14-3-3 protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis [J].
de Seze, J ;
Peoc'h, K ;
Ferriby, D ;
Stojkovic, T ;
Laplanche, JL ;
Vermersch, P .
JOURNAL OF NEUROLOGY, 2002, 249 (05) :626-627
[6]   Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis - Results of a longitudinal magnetic resonance spectroscopy study [J].
De Stefano, N ;
Matthews, PM ;
Fu, LQ ;
Narayanan, S ;
Stanley, J ;
Francis, GS ;
Antel, JP ;
Arnold, DL .
BRAIN, 1998, 121 :1469-1477
[7]   Amyloid beta 1-42, and tau in cerebrospinal fluid after severe traumatic brain injury [J].
Franz, G ;
Beer, R ;
Kampfl, A ;
Engelhardt, K ;
Schmutzhard, M ;
Ulmer, H ;
Deisenhammer, F .
NEUROLOGY, 2003, 60 (09) :1457-1461
[8]   ALZHEIMERS-DISEASE AND DOWNS-SYNDROME - SHARING OF A UNIQUE CEREBROVASCULAR AMYLOID FIBRIL PROTEIN [J].
GLENNER, GG ;
WONG, CW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1984, 122 (03) :1131-1135
[9]   Tau protein seems not to be a useful routine clinical marker of axonal damage in multiple sclerosis [J].
Guimaraes, J ;
Cardoso, MJ ;
Sá, MJ .
MULTIPLE SCLEROSIS, 2006, 12 (03) :354-356
[10]   Core biological marker candidates of Alzheimer's disease -: perspectives for diagnosis, prediction of outcome and reflection of biological activity [J].
Hampel, H ;
Mitchell, A ;
Blennow, K ;
Frank, RA ;
Brettschneider, S ;
Weller, L ;
Möller, HJ .
JOURNAL OF NEURAL TRANSMISSION, 2004, 111 (03) :247-272